CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
我们的工作确立了CD81作为连接放射抵抗与免疫逃逸的关键桥梁,其通过维持GBM中CD274的丰度发挥作用,并突显CD81作为优化放射免疫治疗的有前景的治疗靶点。
英文原题:Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal adenocarcinoma.
circGANAB的上调在PDAC中作为新型诊断生物标志物具有广阔前景。CircGANAB通过降解相互作用的RNA促进PDAC肿瘤生长、转移和免疫治疗耐药。这些结果凸显了circRNA在肿瘤微环境中的重要性以及circRNA-RNA相互作用基因调控机制在肿瘤发生和进展中的基础作用。
环状RNA(circRNA)在癌症中发挥重要作用。然而,它们在胰腺导管腺癌(PDAC)进展和治疗耐药中的作用尚待深入研究。在此,我们研究了circGANAB在PDAC中的作用及诊断潜力。
在PDAC细胞系、肿瘤组织和血清外泌体中检测了circGANAB的水平。构建受试者工作特征曲线以评估circGANAB的诊断性能。在小鼠肿瘤模型中研究了circGANAB在PDAC肿瘤生长、转移和免疫治疗耐药中的致癌作用。进行了circRNA-pulldown,随后进行RNA测序,以鉴定与circGANAB相互作用的RNA。进行了RNA稳定性实验以研究circGANAB在调控其相互作用RNA中的作用。
CircGANAB在PDAC细胞系、原发肿瘤中表达上调,并在转移性肿瘤中进一步上调,与肿瘤大小和不良预后呈正相关。CircGANAB促进PDAC细胞生长、铁死亡抵抗和转移。此外,circGANAB通过抑制CD4+和CD8+ T细胞浸润,限制了抗PD-L1免疫治疗的疗效。在机制上,circGANAB直接与肿瘤抑制性lncRNA GAS5、lncLDAH3和TMEM51-AS1以及mRNA IL-13和IL-17D相互作用,导致RNA降解。此外,血清外泌体circGANAB显著升高,作为一种非侵入性生物标志物具有良好的诊断性能。外泌体介导的致癌性circGANAB在瘤内转移促进了PDAC进展。
AIMS: Circular RNAs (circRNAs) play important roles in cancer. However, their roles in pancreatic ductal adenocarcinoma (PDAC) progression and therapeutic resistance are underexplored. Here, we investigated the roles and diagnostic potential of circGANAB in PDAC. METHODS: The level of circGANAB was examined in PDAC cell lines, tumor tissues and serum exosomes. A receiver operating characteristic curve was constructed to evaluate the diagnostic performance of circGANAB. The oncogenic roles of circGANAB in PDAC tumor growth, metastasis, and immunotherapy resistance were studied in mouse tumor models. CircRNA-pulldown, followed by RNA sequencing, was performed to identify circGANAB-interacting RNAs. RNA stability assay was performed to investigate the roles of circGANAB in regulating its interacting RNAs. RESULTS: CircGANAB was upregulated in PDAC cell lines, primary tumors and was further upregulated in metastatic tumors, with a positive link to the tumor size and poor prognosis. CircGANAB promoted PDAC cell growth, ferroptosis resistance, and metastasis. Furthermore, circGANAB limited anti-PD-L1 immunotherapy efficacy by inhibiting CD4+ and CD8+ T cell infiltration. Mechanistically, circGANAB directly interacted with tumor suppressive lncRNAs GAS5, lncLDAH3, and TMEM51-AS1 and mRNAs IL-13 and IL-17D, resulting in RNA degradation. Additionally, serum exosomal circGANAB significantly increased with good diagnostic performance as a non-invasive biomarker. Exosome-mediated intratumoral transfer of the oncogenic circGANAB promoted PDAC progression. CONCLUSIONS: The upregulated circGANAB holds promising potential as a novel diagnostic biomarker in PDAC. CircGANAB promotes PDAC tumor growth, metastasis, and immunotherapy resistance through degrading interacting RNAs. These results highlight the significance of circRNAs in the tumor microenvironment and the circRNA-RNA interaction gene regulatory mechanisms underlying oncogenesis and tumor progression.
MEMBER ACCOUNT
登录成功会直接打开下一页。